Vertaling van "safe use of medicines that the information " (Nederlands → Frans) :

It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.
It is also essential for rational and safe use of medicines that the information in advertising agrees with the elements approved of when the marketing authorisation (MA) for the medicine was granted. Healthcare professionals when making a therapeutic choice should not be influenced by elements that are not associated with the characteristics of the medicine.

The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.
The FAMHP and the BUM department in particular ensures that all parties have access to such information, so that medicines can be used rationally and safely.

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

Advisory commission that is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (French-speaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacistsclinical biologists Commission for the supervision of advertising for medicines for human use
Advisory commission that is consulted e.g. in cases of non-availability of medicines Commission for the approval of institutions assigning preliminary approvals for scientific events Commission for the establishment of retail pharmacies and chambers of appeal (French-speaking chamber and Dutch-speaking chamber) Commission for the recognition of pharmacistsclinical biologists Commission for the supervision of advertising for medicines for human use

The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.
The prevention of adverse effects and adverse events attributable to the use of medicines and health products is closely linked with information for healthcare professionals and the public regarding the risks associated with the use of medicines and health products.

The roles that pharmacists could play in this issue are: the ability to recognise risk factors such as a previous attempted suicide or the abusive use of medication, referring patients to health professionals when suspecting the early stages of a depression, and also to a certain extent following-up compliance and providing information on the side effects of the medicine.
Les rôles qui pourraient être attribués aux pharmaciens dans la problématique sont: savoir reconnaître les facteurs de risque comme une tentative de suicide antérieure ou l’abus de médicaments problématique, l’orientation vers des intervenants en cas de soupçon de début de dépression, et dans une certaine mesure également, le suivi de la compliance et l’information sur les effets secondaires des médicaments.

Some achievements and figures for Unit II in 2007 Rapid alerts relating to the quality of medicines The Rapid Alerts System or RAS network is an international network whose purpose is to circulate information as quickly as possible about batches of medicines that have been identified as nonconforming, which were produced in non-GMP conditions or which do not belong to the distribution circuit that complies with the GDP.
Some achievements and figures for Unit II in 2007 Rapid alerts relating to the quality of medicines The Rapid Alerts System or RAS network is an international network whose purpose is to circulate information as quickly as possible about batches of medicines that have been identified as nonconforming, which were produced in non-GMP conditions or which do not belong to the distribution circuit that complies with the GDP.

The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.
The R&D (research and development) department of the FAMHP is responsible for the evaluation and approval of clinical research activities, ranging from the first “use” (concept) to extensive trials with medicines that are developed and carried out by university and other research centres and by the pharmaceutical industry.

The primary concern of doctors, pharmacists, and other health professionals is informing their patients and drawing their attention to the fact that it is of crucial importance to use the correct dosage (e.g. by drawing their attention to the potential side effects of a treatment once it has been started and explaining to them that antidepressants need a few weeks to take effect).
La plus grande préoccupation des médecins, pharmaciens et autres prestataires de soins de santé est d’informer les patients sur l’importance d’une posologie correcte et de les informer (par exemple en attirant l’attention sur des possibles effets secondaires d’un traitement entamé et en expliquant que les antidépresseurs ne commencent à être effectifs qu’au bout de quelques semaines).

Scientific research has shown that the spreading of information about suicides by the media has a greater impact on the method used to commit suicide than on its frequency.
La recherche scientifique a montré que la diffusion de l’information sur un suicide par les médias a un impact plus grand sur la méthode de suicide utilisée que la fréquence de suicide elle-même.